Skip to main content

From the helm: Proteomics International (ASX:PIQ), Dr. Richard Lipscombe, Managing Director

Bell Direct
July 7, 2025

In this episode of From the helm, Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.

In this video, Dr. Lipscombe covers:
·      (0:47): An overview of PIQ and its FY26 goals
·      (1:38): The significance of three world-first blood tests
·      (5:26): The global addressable markets for these conditions
·      (6:25): Clinical trial progress and commercialisation roadmap
·      (8:14): How the diagnostic tests work and deliver value to patients
·      (9:16): Commercialisation strategy across key regions
·      (11:23): Additional assets in the PIQ pipeline
·      (12:36): What investors can expect over the next 12 months

Note: This interview was recorded on 3 July 2025.

Morning Bell 25 June

Bell Direct
June 25, 2024

Morning Bell 24 June

Bell Direct
June 24, 2024

Weekly Wrap 21 June

Bell Direct
June 21, 2024

Morning Bell 20 June

Bell Direct
June 20, 2024

Morning Bell 18 June

Bell Direct
June 18, 2024

How to: Directors Interest Tool

Bell Direct
June 17, 2024

How to: Upcoming Dividends tool

Bell Direct
June 17, 2024

How to: Visual Depth Chart

Bell Direct
June 17, 2024

How to: Market to Limit VS Limit

Bell Direct
June 17, 2024

How to: bellinsight

Bell Direct
June 17, 2024